Editas Medicine(US:EDIT) Seeking Alphaยท2024-10-01 23:53Company Overview - Editas Medicine, Inc. is a gene editing company founded approximately 10 years ago and went public about six years ago [3][4] - The company has a strong foundation with licenses to foundational Cas9 and Cas12 enzyme patents, allowing broad applicability in gene editing [3] Current Developments - Editas is at a pivotal moment in its history, having human data for its reni-cel product aimed at treating sickle cell disease [4] - The company is expanding into in vivo gene editing, which is expected to provide more efficient access to a broader patient population [4][5] Product Focus - Reni-cel is an autologous, personalized medicine, indicating a tailored approach to treatment for individual patients [5] - The shift towards in vivo gene editing represents a significant innovation in the medical field, potentially transforming treatment methodologies [5]